MCID: HMT002
MIFTS: 62

Hematologic Cancer

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Hematologic Cancer

MalaCards integrated aliases for Hematologic Cancer:

Name: Hematologic Cancer 12 54 15 37
Hematologic Neoplasm 12 29 6
Hematologic Malignancies 54 15
Hematologic Neoplasms 43 71
Hematopoietic and Lymphoid System Tumor 12
Malignant Hematopoietic Neoplasm 12
Hematopoietic Neoplasms 71
Hematologic Malignancy 12
Hematopoietic Neoplasm 12
Hematological Tumors 12
Hematopoietic Cancer 12
Hematopoietic Tumors 12
Blood Cancer 12
Liquid Tumor 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2531
MeSH 43 D019337
NCIt 49 C27134
UMLS 71 C0376544 C0376545 C3890429

Summaries for Hematologic Cancer

Disease Ontology : 12 An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.

MalaCards based summary : Hematologic Cancer, also known as hematologic neoplasm, is related to bone marrow cancer and mast cell neoplasm. An important gene associated with Hematologic Cancer is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Ceftazidime and Meropenem have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Related Diseases for Hematologic Cancer

Diseases related to Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 869)
# Related Disease Score Top Affiliating Genes
1 bone marrow cancer 33.8 U2AF1 MPL MIR199A1 KIT JAK2 IL3
2 mast cell neoplasm 33.2 U2AF1 KIT IL3 IL2
3 8p11 myeloproliferative syndrome 33.1 RUNX1 KIT FLT3
4 leukemia, acute myeloid 33.1 U2AF1 RUNX1 NUP98 MPL MIR199A1 KMT2A
5 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.0 RUNX1 KMT2A KIT FLT3 ETV6
6 myeloma, multiple 32.6 U2AF1 PVT1 PTHLH MIR199A1 KIT JAK2
7 leukemia, acute lymphoblastic 32.5 XIST U2AF1 RUNX1 PTHLH MPL KMT2A
8 leukemia 32.5 U2AF1 RUNX1 NUP98 MPL KMT2A KIT
9 myelodysplastic syndrome 32.5 U2AF1 RUNX1 NUP98 MPL KMT2A KIT
10 leukemia, chronic lymphocytic 32.4 U2AF1 MIR199A1 KMT2A KIT JAK2 IL2
11 myeloid leukemia 32.3 U2AF1 RUNX1 NUP98 KMT2A KIT JAK2
12 lymphoma, non-hodgkin, familial 32.3 U2AF1 MIR199A1 KMT2A JAK2 IL3 IL2
13 lymphocytic leukemia 32.3 RUNX1 KMT2A IL3 IL2 ETV6 ABL1
14 blood platelet disease 32.3 U2AF1 RUNX1 MPL KIT JAK2 IL3
15 deficiency anemia 32.2 U2AF1 MPL JAK2 IL3 FLT3 CSF3
16 acute leukemia 32.2 RUNX1 NUP98 KMT2A KIT JAK2 IL3
17 aplastic anemia 32.2 U2AF1 MPL IL3 IL2 FLT3 CSF3
18 leukemia, chronic myeloid 32.1 U2AF1 RUNX1 NUP98 MPL KMT2A KIT
19 lymphoma, hodgkin, classic 32.0 PVT1 JAK2 IL3 IL2 CSF3
20 refractory anemia 32.0 RUNX1 MPL IL3 CSF3
21 monocytic leukemia 31.9 RUNX1 KMT2A FLT3
22 leukemia, acute monocytic 31.8 U2AF1 NUP98 KMT2A FLT3
23 juvenile myelomonocytic leukemia 31.8 U2AF1 RUNX1 KMT2A JAK2 FLT3 CBL
24 thrombocytopenia 31.8 U2AF1 RUNX1 MPL JAK2 IL3 IL2
25 myeloid sarcoma 31.8 KMT2A KIT FLT3
26 myelofibrosis 31.8 U2AF1 RUNX1 MPL KIT JAK2 IL3
27 mastocytosis 31.7 KIT JAK2 IL3 FLT3 CBL
28 myeloproliferative neoplasm 31.7 U2AF1 RUNX1 MPL KMT2A KIT JAK2
29 chronic myelomonocytic leukemia 31.6 U2AF1 RUNX1 NUP98 MPL KIT JAK2
30 severe combined immunodeficiency 31.5 KIT IL3 IL2 FLT3 CSF3
31 thrombocytosis 31.5 U2AF1 MPL JAK2 IL3 CSF3
32 acute t cell leukemia 31.5 U2AF1 FLT3 ABL1
33 acute promyelocytic leukemia 31.5 RUNX1 PVT1 NUP98 KMT2A IL3 FLT3
34 stomatitis 31.4 NUP98 IL2 CSF3
35 precursor t-cell acute lymphoblastic leukemia 31.4 NUP98 KMT2A FLT3 ETV6 ABL1
36 severe congenital neutropenia 31.4 JAK2 IL3 IL2 FLT3 CSF3
37 myelodysplastic/myeloproliferative neoplasm 31.4 U2AF1 KMT2A JAK2 FLT3 ETV6 CBL
38 megakaryocytic leukemia 31.4 U2AF1 RUNX1 KMT2A JAK2 IL3
39 polycythemia vera 31.4 MPL KIT JAK2 IL3 ETV6 CSF3
40 pancytopenia 31.3 U2AF1 RUNX1 MPL KMT2A KIT IL3
41 essential thrombocythemia 31.3 U2AF1 MPL KIT JAK2 IL3 CSF3
42 paraneoplastic syndromes 31.3 PTHLH CSF3
43 mucositis 31.3 IL3 IL2 CSF3
44 chronic eosinophilic leukemia 31.3 U2AF1 KIT JAK2 FLT3 ETV6 ABL1
45 neutrophilia, hereditary 31.3 U2AF1 PTHLH JAK2 IL3 FLT3 CSF3
46 exanthem 31.3 KIT IL2 FLT3 CSF3
47 gastrointestinal stromal tumor 31.2 KIT JAK2 FLT3 CCDC26 CBL ABL1
48 thyroid gland cancer 31.2 U2AF1 PVT1 MIR199A1 KIT FLT3 ABL1
49 leukemia, acute lymphoblastic 3 31.2 RUNX1 KMT2A FLT3 ETV6 ABL1
50 chronic leukemia 31.2 U2AF1 KIT JAK2 FLT3 ABL1

Graphical network of the top 20 diseases related to Hematologic Cancer:



Diseases related to Hematologic Cancer

Symptoms & Phenotypes for Hematologic Cancer

GenomeRNAi Phenotypes related to Hematologic Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.1 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.1 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.1 ABL1 FLT3 KIT

MGI Mouse Phenotypes related to Hematologic Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 ABL1 CBL ETV6 FLT3 IL2 JAK2
2 growth/size/body region MP:0005378 10.15 ABL1 CBL ETV6 FLT3 IL2 JAK2
3 hematopoietic system MP:0005397 10.13 ABL1 CBL CSF3 ETV6 FLT3 IL2
4 immune system MP:0005387 10.07 ABL1 CBL CSF3 ETV6 FLT3 IL2
5 endocrine/exocrine gland MP:0005379 10.06 ABL1 CBL ETV6 FLT3 IL2 JAK2
6 liver/biliary system MP:0005370 9.76 ABL1 CBL IL2 JAK2 KIT KMT2A
7 neoplasm MP:0002006 9.56 ETV6 FLT3 IL2 JAK2 KIT KMT2A
8 respiratory system MP:0005388 9.17 ABL1 CBL IL2 JAK2 KIT PTHLH

Drugs & Therapeutics for Hematologic Cancer

Drugs for Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 528)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
2
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
3
Voriconazole Approved Phase 4 137234-62-9 71616
4
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
5
Zinc Approved, Investigational Phase 4 7440-66-6 32051
6
Protein C Approved Phase 4
7
Colistin Approved Phase 4 1066-17-7, 1264-72-8 5311054
8
Busulfan Approved, Investigational Phase 4 55-98-1 2478
9
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
10 Daratumumab Approved Phase 4 945721-28-8
11
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
12
Ofloxacin Approved Phase 4 82419-36-1 4583
13
Liraglutide Approved Phase 4 204656-20-2 44147092
14
Glucagon Approved Phase 4 16941-32-5
15
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
16
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
17
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
18
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
19 Lactams Phase 4
20 beta-Lactams Phase 4
21 penicillins Phase 4
22 Epoetin alfa Phase 4 113427-24-0
23 Drotrecogin alfa activated Phase 4
24 Thymoglobulin Phase 4
25 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Anti-Inflammatory Agents, Non-Steroidal Phase 4
28 Cyclooxygenase Inhibitors Phase 4
29 Incretins Phase 4
30 Hypoglycemic Agents Phase 4
31 Glucagon-Like Peptide 1 Phase 4
32 Cyclooxygenase 2 Inhibitors Phase 4
33 Antiparasitic Agents Phase 4
34 Antiprotozoal Agents Phase 4
35 Pharmaceutical Solutions Phase 4
36 Cytochrome P-450 CYP3A Inhibitors Phase 4
37 Cytochrome P-450 Enzyme Inhibitors Phase 4
38 Steroid Synthesis Inhibitors Phase 4
39 Liposomal amphotericin B Phase 4
40 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
41
Hydroxyitraconazole Phase 4
42
Imiquimod Approved, Investigational Phase 2, Phase 3 99011-02-6 57469
43
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
44
Piperacillin Approved Phase 3 66258-76-2 43672
45
Tazobactam Approved Phase 3 89786-04-9 123630
46
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
47
Denosumab Approved Phase 3 615258-40-7
48
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
49
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
50
Febuxostat Approved Phase 3 144060-53-7 134018

Interventional clinical trials:

(show top 50) (show all 1311)
# Name Status NCT ID Phase Drugs
1 Pilot Study About Viability and Efficacy of Intrabone Administration of Umbilical Cord Blood for Allogeneic Stem Cell Transplantation Unknown status NCT00838019 Phase 4
2 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
3 Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Unknown status NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
4 Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
5 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
6 Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
7 Optimizing Treatment of the Anaemia in Onco-Hematological Diseases With NeoRecormon 30,000 IU Once Weekly Completed NCT02564094 Phase 4 Epoetin beta
8 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
9 An Open-label Non-randomized Phase IV Trial of the Clinical Efficacy of Intravenously Administered 1000mg Paracetamol as Antipyretic and Analgesic Medication Completed NCT01070732 Phase 4 Paracetamol
10 A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support Completed NCT00449592 Phase 4 Zinc;Placebo
11 Early Application of CPAP in Hematologic Neutropenic Patients Avoid Acute Respiratory Failure Completed NCT00507533 Phase 4
12 A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Completed NCT01416025 Phase 4 Prospective TDM Arm
13 A Safety Evaluation of Xigris Drotrecogin Alfa Activated in Hematopoietic Stem Cell Transplant Patients With Severe Sepsis Completed NCT00067730 Phase 4 Drotrecogin Alfa (activated)
14 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
15 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
16 A Randomized Clinical Study of the Decolonization of MDR Gram-negative Bacteria in Patients With Haematological Malignancies Completed NCT02966457 Phase 4 Colistimethate Sodium
17 Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
18 Multicenter, Randomised Study of the Use of Non-Invasive Ventilation (NIV) Versus Oxygen Therapy (O2) in Reducing Dyspnea in End-stage Solid Cancer Patients With Respiratory Failure and Distress Completed NCT00533143 Phase 4
19 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
20 Human Papillomavirus Antibody Response After GARDASIL 9 Vaccination in Patients After Allogeneic Stem Cell Transplantation Recruiting NCT03023631 Phase 4
21 A Multicenter Study to Explore the Mechanism of Acquired Immune Escape In Patients With Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy Recruiting NCT03333655 Phase 4
22 Shanghai General Hospital Affiliated to Shanghai Jiao Tong University Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
23 Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease Recruiting NCT03844360 Phase 4 Bortezomib;Eltrombopag;Imatinib;dasatinib;Pegaspargase;Anti-Infective Drugs
24 RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
25 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
26 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
27 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
28 Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA) Not yet recruiting NCT02920190 Phase 4 Liraglutide
29 The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children Not yet recruiting NCT01344200 Phase 4 Celecoxib
30 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
31 A Multicenter, Randomized Trial Comparing The Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Subjects With Hematological Malignancy Terminated NCT02895529 Phase 4 Itraconazole;Caspofungin
32 A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
33 Evaluation of Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
34 Phase III Trial of 6 Weeks of Imiquimod for the Treatment of Bowens Disease of the Head and Neck. Outcome is Histologic Clearance at 14 Weeks. Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
35 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
36 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
37 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
38 Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
39 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
40 A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma Completed NCT00044759 Phase 3 Piperacillin/Tazobactam (Tazocin)
41 Kinetics of 1, 3 Beta-d- Glucan Assay in Patients With Hematologic Malignancies Receiving Voriconazole Prophylaxis Completed NCT00904995 Phase 3 Voriconazole;Voriconazole
42 Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed NCT00602420 Phase 3 naproxen
43 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
44 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01437787 Phase 3 SAR302503;Placebo
45 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
46 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT01530581 Phase 3
47 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma Completed NCT01345019 Phase 3 Denosumab;Zoledronic acid;Placebo to Denosumab;Placebo to zoledronic acid
48 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
49 A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment Completed NCT01854567 Phase 3
50 Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (BMT CTN #0501) Completed NCT00412360 Phase 3 Cyclophosphamide;Fludarabine;Cyclosporine A;Mycophenolate Mofetil

Search NIH Clinical Center for Hematologic Cancer

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hematologic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hematologic Cancer:
Ducord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Co-infusion of umbilical cord blood and haploidentical CD34+ cells for hematological diseases
StemEx, umbilical cord blood stem/progenitor cells for hematological diseases
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hematopoietic stem cells for treatment of hematologic malignancies
Allocord, cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Expanded cord blood hematopoietic stem cells for hematologic malignancies
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Hematologic Cancer:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905
Umbilical cord blood-derived hematopoietic progenitor cells (Allocord) PMIDs: 11953027
Umbilical cord blood-derived hematopoietic progenitor cells (Ducord) PMIDs: 22698485 21810098 21277377 23711284
Expanded umbilical cord blood-derived hematopoietic stem cells PMIDs: 21396596
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 21396596
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 20676147
Peripheral blood-derived hematopoietic stem cells
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: hematologic neoplasms

Genetic Tests for Hematologic Cancer

Genetic tests related to Hematologic Cancer:

# Genetic test Affiliating Genes
1 Hematologic Neoplasm 29 H3C2

Anatomical Context for Hematologic Cancer

MalaCards organs/tissues related to Hematologic Cancer:

40
T Cells, Bone, Bone Marrow, Myeloid, B Cells, Lung, Testes

Publications for Hematologic Cancer

Articles related to Hematologic Cancer:

(show top 50) (show all 942)
# Title Authors PMID Year
1
Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. 54 61
16788155 2006
2
Plasma PTH and PTH-rP levels and clodronate therapy in cancer patients with hypercalcemia. 54 61
7910069 1993
3
Isoferulic acid inhibits human leukemia cell growth through induction of G2/M‑phase arrest and inhibition of Akt/mTOR signaling. 61
31922221 2020
4
Nurse Case Manager: Measurement of Care Coordination Activities and Quality and Resource Use Outcomes When Caring for the Complex Patient With Hematologic Cancer. 61
31961839 2020
5
The experience of financial stress among emerging adult cancer survivors. 61
31983313 2020
6
Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression. 61
31898443 2020
7
Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. 61
31958813 2020
8
Loss of KDM6A confers drug resistance in acute myeloid leukemia. 61
31201358 2020
9
The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia. 61
31902138 2020
10
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date. 61
32021432 2020
11
Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications. 61
30939217 2019
12
FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways. 61
30975911 2019
13
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. 61
31847174 2019
14
CAR T cell therapy: A new era for cancer treatment (Review). 61
31578576 2019
15
Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature. 61
31807922 2019
16
The Epidemiology of Sepsis in Chinese ICUs: A National Cross-Sectional Survey. 61
31804299 2019
17
CE: Hematologic Childhood Cancers: An Evidence-Based Review. 61
31764050 2019
18
Augmented Renal Clearance of Vancomycin in Hematologic Malignancy Patients. 61
31534058 2019
19
Depression and anxiety in older patients with hematological cancer (70+) - Geriatric, social, cancer- and treatment-related associations. 61
31831361 2019
20
Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study. 61
31901718 2019
21
Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea. 61
31820128 2019
22
Improvements in Sepsis-Associated Mortality in Hospitalized Cancer vs Non-Cancer Patients: A 12-Year Analysis Using Clinical Data. 61
31800299 2019
23
Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients. 61
31481441 2019
24
The Impact of Hematologic Cancer and Its Treatment on Physical Activity Level and Quality of Life Among Children in Mainland China: A Descriptive Study. 61
30433896 2019
25
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. 61
31699827 2019
26
A consensus document for the clinical management of invasive fungal diseases in pediatric patients with hematologic cancer and/or undergoing hematopoietic stem cell transplantation in Brazilian medical centers. 61
31738887 2019
27
Residential ambient benzene exposure in the United States and subsequent risk of hematologic malignancies. 61
30737780 2019
28
Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications. 61
31173533 2019
29
Factors Associated With Uncertainty in Patients Scheduled to Undergo Hematopoietic Stem Cell Transplantation. 61
31652135 2019
30
Discovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors. 61
31301565 2019
31
Clinicopathologic Assessment of Monoclonal Immunoglobulin-Associated Renal Disease in the Kidney Allograft. A Retrospective Study and Review of the Literature. 61
31634325 2019
32
Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth. 61
31251903 2019
33
Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia. 61
31399482 2019
34
Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13. 61
31538911 2019
35
Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. 61
31531319 2019
36
Temporal Trends in the Use of Acute Recanalization Therapies for Ischemic Stroke in Patients with Cancer. 61
31153762 2019
37
Mindfulness, Experiential Avoidance, and Recovery From Hematopoietic Stem Cell Transplantation. 61
30624541 2019
38
Individual and Dyadic Coping and Fear of Progression in Mothers and Fathers of Children with Hematologic Cancer. 61
31408204 2019
39
Neurophysiological evidence of impaired attention and working memory in untreated hematologic cancer patients. 61
31163369 2019
40
A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. 61
31350306 2019
41
Correction: AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. 61
31262746 2019
42
"I Am Sure That They Use My PROM Data for Something Important." A Qualitative Study About Patients' Experiences From a Hematologic Outpatient Clinic. 61
31361675 2019
43
Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ. 61
31346210 2019
44
A prospective study examining cachexia predictors in patients with incurable cancer. 61
31164115 2019
45
Relevant updates in systemic mastocytosis. 61
30978435 2019
46
Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. 61
31216696 2019
47
Binary Targeting of siRNA to Hematologic Cancer Cells In Vivo using Layer-by-Layer Nanoparticles. 61
31839764 2019
48
I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma. 61
30455393 2019
49
Primary and Secondary Breast Lymphoma: Clinical, Pathologic, and Multimodality Imaging Review. 61
30924754 2019
50
Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. 61
30467206 2019

Variations for Hematologic Cancer

ClinVar genetic disease variations for Hematologic Cancer:

6 (show all 18) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ETV6 NM_001987.4(ETV6):c.1106G>A (p.Arg369Gln)SNV Pathogenic 162221 rs724159946 12:12037475-12037475 12:11884541-11884541
2 ETV6 NM_001987.4(ETV6):c.1195C>T (p.Arg399Cys)SNV Pathogenic 162220 rs724159945 12:12038902-12038902 12:11885968-11885968
3 CBL NM_005188.3(CBL):c.1111T>C (p.Tyr371His)SNV Pathogenic 13811 rs267606706 11:119148891-119148891 11:119278181-119278181
4 KIT NM_000222.2(KIT):c.2446G>C (p.Asp816His)SNV Pathogenic 13863 rs121913506 4:55599320-55599320 4:54733154-54733154
5 MPL NM_005373.2(MPL):c.1544G>T (p.Trp515Leu)SNV Pathogenic 14164 rs121913615 1:43815009-43815009 1:43349338-43349338
6 insertion Pathogenic 627427
7 Translocation Pathogenic 627428
8 CBL NM_005188.3(CBL):c.1150T>C (p.Cys384Arg)SNV Pathogenic/Likely pathogenic 29822 rs387906664 11:119148930-119148930 11:119278220-119278220
9 KIT NM_000222.2(KIT):c.1924A>G (p.Lys642Glu)SNV Pathogenic/Likely pathogenic 13866 rs121913512 4:55594221-55594221 4:54728055-54728055
10 ETV6 NM_001987.4(ETV6):c.641C>T (p.Pro214Leu)SNV Pathogenic/Likely pathogenic 162222 rs724159947 12:12022535-12022535 12:11869601-11869601
11 KIT NM_000222.2(KIT):c.2446G>T (p.Asp816Tyr)SNV Pathogenic/Likely pathogenic 13860 rs121913506 4:55599320-55599320 4:54733154-54733154
12 CSF1R NM_005211.3(CSF1R):c.1711T>G (p.Tyr571Asp)SNV Likely pathogenic 376166 rs1057519802 5:149441328-149441328 5:150061765-150061765
13 CSF1R NM_005211.3(CSF1R):c.2906A>T (p.Tyr969Phe)SNV Likely pathogenic 376270 rs1801271 5:149433645-149433645 5:150054082-150054082
14 CSF1R NM_005211.3(CSF1R):c.2906A>G (p.Tyr969Cys)SNV Likely pathogenic 376271 rs1801271 5:149433645-149433645 5:150054082-150054082
15 CSF1R NM_005211.3(CSF1R):c.2905T>C (p.Tyr969His)SNV Likely pathogenic 376272 rs121913393 5:149433646-149433646 5:150054083-150054083
16 CSF1R NM_005211.3(CSF1R):c.902T>C (p.Leu301Ser)SNV Likely pathogenic 376273 rs121913390 5:149453044-149453044 5:150073481-150073481
17 CSF1R NM_005211.3(CSF1R):c.903G>T (p.Leu301Phe)SNV Likely pathogenic 376703 rs1057520014 5:149453043-149453043 5:150073480-150073480
18 KIT NM_000222.2(KIT):c.2447A>T (p.Asp816Val)SNV Uncertain significance 13852 rs121913507 4:55599321-55599321 4:54733155-54733155

Expression for Hematologic Cancer

Search GEO for disease gene expression data for Hematologic Cancer.

Pathways for Hematologic Cancer

Pathways related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 KIT JAK2 IL3 IL2 H3C2 FLT3
2
Show member pathways
13.42 MPL KIT JAK2 IL3 IL2 H3C2
3
Show member pathways
13.17 NUP98 KIT JAK2 IL3 IL2 H3C2
4
Show member pathways
12.85 KIT JAK2 IL3 IL2 FLT3 CSF3
5
Show member pathways
12.7 RUNX1 KIT IL3 FLT3 CBL ABL1
6 12.28 RUNX1 KIT JAK2 IL3 IL2 FLT3
7
Show member pathways
12.26 KIT IL3 IL2 FLT3 CBL
8 12.21 RUNX1 MPL KIT JAK2 IL3 IL2
9
Show member pathways
12.19 JAK2 IL3 FLT3 CBL
10
Show member pathways
12.13 MPL JAK2 IL3 IL2 CSF3
11
Show member pathways
12.02 KIT JAK2 IL3 CBL
12 12 RUNX1 KMT2A IL3 H3C2 FLT3 ETV6
13 11.89 KIT JAK2 FLT3 CBL ABL1
14 11.74 JAK2 IL3 IL2 ABL1
15 11.73 KIT IL3 FLT3 CSF3
16 11.66 RUNX1 KIT IL2
17 11.6 KIT IL2 FLT3
18 11.38 RUNX1 IL3 CSF3
19 11.16 MPL KIT IL3 IL2 FLT3 CSF3
20 11.1 IL3 IL2 CSF3
21 10.9 KIT IL3 IL2 FLT3 CSF3
22 10.81 KIT CBL

GO Terms for Hematologic Cancer

Biological processes related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.8 KIT JAK2 IL3 IL2 FLT3
2 positive regulation of cell proliferation GO:0008284 9.8 PTHLH KIT JAK2 IL3 IL2 FLT3
3 protein autophosphorylation GO:0046777 9.78 KIT JAK2 FLT3 ABL1
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.76 MIR199A1 JAK2 IL2 ABL1
5 hemopoiesis GO:0030097 9.73 RUNX1 KIT FLT3
6 peptidyl-tyrosine phosphorylation GO:0018108 9.73 KIT JAK2 FLT3 ABL1
7 regulation of megakaryocyte differentiation GO:0045652 9.71 RUNX1 KMT2A H3C2
8 regulation of hematopoietic stem cell differentiation GO:1902036 9.7 RUNX1 KMT2A ABL1
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 JAK2 IL3 CSF3 ABL1
10 regulation of regulatory T cell differentiation GO:0045589 9.59 RUNX1 IL2
11 negative regulation of cell-cell adhesion GO:0022408 9.58 JAK2 ABL1
12 hematopoietic stem cell proliferation GO:0071425 9.58 RUNX1 ETV6
13 mast cell degranulation GO:0043303 9.57 KIT CBL
14 negative regulation of heart contraction GO:0045822 9.55 JAK2 IL2
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.55 KIT JAK2 FLT3 CSF3 CBL
16 regulation of cytokine-mediated signaling pathway GO:0001959 9.51 RUNX1 IL3
17 embryonic hemopoiesis GO:0035162 9.5 KMT2A KIT IL3
18 myeloid progenitor cell differentiation GO:0002318 9.49 KIT FLT3
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.35 KIT JAK2 IL3 IL2 FLT3
20 cytokine-mediated signaling pathway GO:0019221 9.23 MPL KIT JAK2 IL3 IL2 FLT3

Molecular functions related to Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide hormone receptor binding GO:0051428 9.16 PTHLH JAK2
2 SH2 domain binding GO:0042169 9.13 KIT JAK2 ABL1
3 protein tyrosine kinase activity GO:0004713 8.92 KIT JAK2 FLT3 ABL1

Sources for Hematologic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....